None PI Major Mutations: PI Accessory Mutations: None PR Other Mutations: 113V -- K20R -- E35D -- M36I -- R41K -- R57K -- H69K -- K70R -- 172IV -- E89M --

HIVDB 9.5.1 (2023-11-05)

## Protease Inhibitors

Drug resistance interpretation: PR

atazanavir/r (ATV/r) Susceptible darunavir/r (DRV/r) Susceptible Susceptible fosamprenavir/r (FPV/r) indinavir/r (IDV/r) Susceptible lopinavir/r (LPV/r) Susceptible nelfinavir (NFV) Susceptible

## PR comments

Mutation scoring: PR

abacavir (ABC)

zidovudine (AZT)

saquinavir/r (SQV/r)

tipranavir/r (TPV/r)

## Other

K20R is a highly polymorphic PI-selected accessory mutation that increases replication fitness in viruses with PI-resistance mutations.

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT

NRTI Mutations:

NNRTI Mutations: RT Other Mutations:

None K103N \*\*\*

Susceptible

Susceptible

Nucleoside Reverse Transcriptase Inhibitors Non-nucleoside Reverse Transcriptase Inhibitors doravirine (DOR) Susceptible Susceptible Susceptible efavirenz (EFV) High-Level Resistance

etravirine (ETR)

nevirapine (NVP)

rilpivirine (RPV)

stavudine (D4T) Susceptible didanosine (DDI) Susceptible emtricitabine (FTC) Susceptible lamivudine (3TC) tenofovir (TDF)

Susceptible Susceptible

RT comments NNRTI

Other

. V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.

No drug resistance mutations were found for NRTI.

Mutation scoring: RT

Drug resistance mutation scores of NNRTI: DOR # EFV ETR ≑ NVP ≑ 60 60 K103N 0 0

RPV 0

Drug resistance interpretation: IN

INSTI Major Mutations:

T97TA NAME AND INSTI Accessory Mutations:

None

IN Other Mutations: K14R = . 160M = . 172V = . 120E = . 120F = . 120 Integrase Strand Transfer Inhibitors

Susceptible


Susceptible

High-Level Resistance

## bictegravir (BIC) Susceptible

cabotegravir (CAB) Susceptible dolutegravir (DTG) Susceptible elvitegravir (EVG) raltegravir (RAL)

Potential Low-Level Resistance Potential Low-Level Resistance



Drug resista	istance mutation scores of INSTI:			Down	
Rule	BIC ≑	CAB ≑	DTG ÷	EVG :	
<u>T97TA</u>	0	0	0	10	